DAVID S. GRAYZEL
CIK 1732786 · last filed 2026-01-30
DAVID S. GRAYZEL is a corporate insider who has filed 24 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing, for QTTB, was dated Jan 30, 2026. Across all open-market trades the lifetime net is −$35.9M, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
3
24
-$35.87M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| QTTB | Director | — | $12.64 | — | $0 | 5 | 2026-01-30 |
| Jade Biosciences, Inc. (AVTE) Delisted | Director | 1,784,730 | $93.80 | $167.41M | $7.17M | 9 | 2024-06-07 |
| Surface Oncology, Inc. (SURF) Delisted | Director | 0 | $1.07 | $0 | -$43.04M | 10 | 2023-09-08 |
Recent Filings
24 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-01-30 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2025-10-27 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2025-02-26 | QTTB | Mixed | — | $0 | EDGAR |
| 2024-08-14 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Jade Biosciences, Inc. (AVTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-11 | Jade Biosciences, Inc. (AVTE) Delisted | Sell (S) | −11,882 | -$334.5K | EDGAR |
| 2024-03-27 | QTTB | Grant (A) | — | $0 | EDGAR |
| 2024-01-04 | Jade Biosciences, Inc. (AVTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-09-08 | Surface Oncology, Inc. (SURF) Delisted | Disp (D) | −2,945,453 | $0 | EDGAR |
| 2023-06-08 | Jade Biosciences, Inc. (AVTE) Delisted | Grant (A) | — | $0 | EDGAR |